Aiwu Ruth He, MD, PhD

Aiwu Ruth He, MD, PhD, is a gastrointestinal medical oncologist at the MedStar Health Lombardi Cancer Center

Articles by Aiwu Ruth He, MD, PhD

Aiwu Ruth He, MD, PhD, a gastrointestinal medical oncologist at the MedStar Health Lombardi Cancer Center

Dr He on the FDA Approval of Nivolumab Plus Ipilimumab for Unresectable/Metastatic HCC

April 11th 2025

Aiwu Ruth He, MD, PhD, discusses the significance of data from the CheckMate 9DW trial evaluating frontline nivolumab plus ipilimumab in metastatic HCC.

Dr He on the Evaluation of Camrelizumab Plus Rivoceranib in Unresectable HCC

ByAiwu Ruth He, MD, PhD

January 4th 2024

Aiwu Ruth He, MD, PhD, discusses the evaluation of camrelizumab plus rivoceranib in unresectable hepatocellular carcinoma.

Advanced Biliary Tract Cancers: Novel Biomarker Strategies

ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD

November 9th 2022

Closing out their discussion on the management of biliary tract cancers, experts share excitement for future evolutions in the treatment landscape.

Novel Agents Being Explored in Advanced Biliary Tract Cancers

ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD

November 9th 2022

Expert panelists provide comprehensive insight on novel targeted agents being investigated in advanced biliary tract cancers.

Sequencing Therapy in Patients With Advanced Biliary Tract Cancers

ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD

November 2nd 2022

In the context of advanced biliary tract cancers, panelists reflect on the optimal sequencing of agents throughout multiple lines of therapy.

Advanced Biliary Tract Cancers: Managing Immunotherapy-Related Adverse Events

ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD

November 2nd 2022

Expert perspectives on the toxicity profile of immunotherapy agents and how they can be managed in patients being treated for advanced biliary tract cancers.

Advanced BTC: Informing Use of IO Therapy in Specific Patient Populations

ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD

October 26th 2022

Shared insight on efforts to identify patient subgroups that may benefit more from immunotherapy in the setting of advanced biliary tract cancers.

TOPAZ-1: Durvalumab + Doublet Chemotherapy in Advanced Biliary Tract Cancers

October 26th 2022

Centering their conversation on the TOPAZ-1 clinical trial, expert panelists review the use of IO + chemotherapy in advanced biliary tract cancers.

Advanced Biliary Tract Cancers: First- and Second-Line Chemotherapy

ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD

October 19th 2022

Focused discussion on chemotherapy treatment options commonplace in patients with advanced or metastatic biliary tract cancers.

An Overview of Systemic Therapy for Advanced Biliary Tract Cancers

ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD

October 19th 2022

Shifting their focus to the advanced disease setting, panelists provide a comprehensive overview on systemic treatment modalities used in biliary tract cancers.

Understanding the Role of Adjuvant Therapy in Biliary Tract Cancers

ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD

October 12th 2022

Experts provide brief perspective on the use of adjuvant treatment approaches for patients with biliary tract cancers.

What is the Role of Transplant in Early-Stage Biliary Tract Cancers?

ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD

October 12th 2022

Before closing out their review of early-stage biliary tract cancer treatment options, panelists consider the role of transplant in the setting.

Treatment Options for Early-Stage Biliary Tract Cancers

October 5th 2022

Centering discussion on early-stage biliary tract cancers, expert panelists consider the respective roles of surgery and embolization strategies in this setting.

Guidelines for Molecular Testing in Biliary Tract Cancers

October 5th 2022

Panelists share their perspectives on molecular testing guidelines for patients diagnosed with biliary tract cancers.

Biliary Tract Cancers: Staging and Clinicopathologic Features

September 28th 2022

Comprehensive insight on staging biliary tract cancers followed by an overview of molecular testing and targetable clinicopathologic features.

Challenges in Diagnosing Biliary Tract Cancers

September 28th 2022

Expert perspectives on the presentation of biliary tract cancers with specific insight to the challenges inherent in reaching a timely diagnosis.

Incidence and Risk Factors for Biliary Tract Cancers

September 21st 2022

Shared insight on the global incidence of biliary tract cancers and which risk factors most impact the likelihood of disease.

An Overview on Biliary Tract Cancers

ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Mark Yarchoan, MD,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University

September 21st 2022

Opening their discussion on biliary tract cancers, a multidisciplinary panel of experts consider how specific subsets of these malignancies differ from one another.

Dr. He on the Future of Durvalumab Plus Chemotherapy in Biliary Tract Cancer

ByAiwu Ruth He, MD, PhD

August 12th 2022

Aiwu Ruth He, MD, PhD, discusses next steps for durvalumab in combination with gemcitabine plus cisplatin in patients with advanced biliary tract cancer.

Dr. He on the Future of Precision Medicine in GI Malignancies

ByAiwu Ruth He, MD, PhD

February 27th 2018

Aiwu Ruth He, MD, PhD, associate professor of medicine, Georgetown-Lombardi Comprehensive Cancer Center, discusses the future of precision medicine in gastrointestinal malignancies.

Dr. He on the Potential of Immune Checkpoint Inhibitors in GI Cancers

ByAiwu Ruth He, MD, PhD

February 13th 2018

Aiwu Ruth He, MD, PhD, associate professor of medicine, Georgetown-Lombardi Comprehensive Cancer Center, summarizes current treatment approaches in gastrointestinal (GI) cancers.